Needle-free delivery of powdered protein vaccines: A new and rapidly developing technique

Journal of Pharmaceutical Innovation

Volumn 3, Issue 3, 2008, Pages 204-213

  Ziegler, Andreas S ^a  

^a NONE   (Germany)

Author keywords

Epidermal powder immunization; Needle free injection; Particle formulations; Protein stabilization; Spray freeze drying

Indexed keywords

ALGINIC ACID; AMINO ACID; ANTIGEN; CARBOHYDRATE; CARRAGEENAN; CHITIN; CHITOSAN; COLLAGEN; DEXTRAN; DISACCHARIDE; DNA VACCINE; GELATIN; HEPATITIS B VACCINE; INFLUENZA VACCINE; MACROGOL; MONOSACCHARIDE; POLOXAMER; POLYANHYDRIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYMETHACRYLIC ACID; POLYOL; POLYPEPTIDE; POLYVINYL ALCOHOL; STARCH; SUGAR; SURFACTANT; VACCINE;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG STABILITY; DRY POWDER; EPIDERMAL POWDER IMMUNIZATION; FREEZE DRYING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INJECTION PISTOL; JET INJECTION; MATHEMATICAL MODEL; NEEDLE FREE POWDER INJECTION; PARTICLE MEDIATED DNA IMMUNIZATION; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION;

EID: 52549101946     PISSN: 18725120     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12247-008-9039-x     Document Type: Review

References (62)

1. Bos J, Kapsenberg ML. The skin immune system: Progress in cutaneous biology. Immunol Today 1993;14(2):75-8.
2. Cruz P, Bergstresser PR. Antigen processing and presentation by epidermal Langerhans cells: Induction of immunity or unresponsiveness. Dermatol Clin 1990;8(4):633-47.
3. Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 2004;23:681-6.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52.
5. Barrett AW, Cruchley AT, Williams DM. Oral mucosal Langerhans' cells. Crit Rev Oral Biol Med 1996;7(1):36-58.
6. Bos JD. The skin immune system (SIS). In: Bos JD, editor. Cutaneous immunology and clinical immunodermatology. Boca Raton, FL: CRC; 1997.
7. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999;162(5):2472-5.
8. Romani N, Schuler G. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Springer Semin Immunopathol 1992;13(3-4):265-79.
9. Schwarzenberger K, Udey MC. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J Invest Dermatol 1996;106(3):553-8.
10. Dean HJ, Fuller D, Osorio JE. Powder an particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 2003;26:373-88.
11. Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992;52:1-123.
12. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-50.
13. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs. Nature 1998;392(6671):86-9.
14. Schirnbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 1995;13(9):857-65.
15. Bogunovic M, Ginhoux F, Wagers A, Loubeau M, Isola LM, Lubrano L, Najfeld V, Phelps RG, Grosskreutz C, Scigliano E, Frenette PS, Merad M. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med 2006;203:2627-38.
16. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 2007;8:578-83.
17. Mayfield E. Protecting patients and professionals from blood-borne disease. FDA Consum Magazine 1993;2783:9-13.
18. Kurugöl Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine 2001;19(28-29):3936-9.
19. Bellanti JA, Zeligs BJ, Mendez de Inocencio J, Omidvar BM, Omidvar J, Awasum M. Alternative routes of immunization for prevention of infectious diseases: A new paradigm for the 21st century. Allergy Asthma Proc 2001;22(3):173-6.
20. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000;21(4):264-9.
21. Burkoth TL. Drug delivery by transdermal and transmucosal powder injection. The Drug Delivery Companies Report; 2001. pp. 76-8.
22. Burkoth TL, Bellhouse BJ, Hewson G, Longridge DL, Muddle AG, Sarphie DF. Transdermal and transmucosal powdered drug delivery. Crit Rev Ther Drug Carr Syst 1999;16(4):331-84.
23. Mitchell TJ, Kendall MAF, Bellhouse BJ. Micro-particle penetration to the oral mucosa. Bioengineering Conference ASME. BED 2001;50:763-4.
24. Kendall MAF, Mitchell TJ, Hardy MP, Bellhouse BJ. The ballistic delivery of high density, high-velocity microparticles into excised human skin. Proceedings of the Bioengineering Conference. BED (American Society of Mechanical Engineers) 2001;50:587-8.
25. Sarphie DF, Johnson B, Cormier M, Burkoth TL, Bellhouse BJ. Bioavailability following transdermal powdered delivery (TPD) of radiolabeled inulin to hairless guinea pigs. J Control Release 1997;47:61-9.
26. Kendall M, Mitchell T, Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J Biomech 2004;37:1733-41.
27. Kendall M. Pharmaceutical delivery to skin and mucosal surfaces. Lecture script, University of Oxford. 2003.
28. Awerbuch J. A mechanics approach to projectile penetration Israel. J Technol 1970;8(4):375-83.
29. Dehn J. A unified theory of penetration. Int J Impact Eng 1987;5:239-48
30. Kendall M, Rishworth S, Carter F, Mitchell T. Effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles to excised porcine skin. J Invest Dermatol 2004;122:739-46.
31. Mitchell TM. The ballistics of micro-particles into the mucosa and skin. DPhil thesis, Engineering Science, University of Oxford. 2003.
32. Mitchell TM, Kendall MAF, Bellhouse BJ. A ballistic study of micro-particle penetration to the oral mucosa. Int J Impact Eng 2003;28:581-99.
33. Kendall M, Mitchell T, Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for drug and vaccine applications. J Biomech 2004;37(11):1733-41.
34. Wildnauer RH, Bothwell JW, Douglas AB. Stratum corneum properties I. Influence of relative humidity on normal and extracted stratum corneum. J Invest Dermatol 1971;56:72-8.
35. Kishino A, Yanagida T. Force measurements by micromanipulation of a single actin filament by glass needles. Nature 1988;334:74-6.
36. Duck FA. Physical properties of tissue: A comprehensive reference book. London: Academic; 1990.
37. Sarphie DF, Burkoth TL. Method for providing dense particle compositions for use in transdermal particle delivery. PCT Int. Apll. (1997) 31 pp.
38. Prestrelski SJ, Burkoth TL, Maa Y-F. Production of hard, dense particles. WO02100380 PCT Int. Appl. (2002).
39. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 2002;4:428-37.
40. Kuo JS, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: Effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol 2004;56:27-33.
41. Masters K. Spray drying handbook. New York: Wiley; 1991.
42. Nürnberg E. Darstellung und Eigenschaften pharmazeutisch relevanter Sprühtrocknungsprodukte, eine Übersicht. Acta Pharm Technol 1980;26(1):39-67.
43. Sacchetti M, Van Oort MM. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, editor. Inhalation aerosols. Physical and biological basis for therapy. New York: Marcel Dekker; 1996.
44. Maa Y-F, Prestrelski SJ. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotech 2000;1:283-302.
45. Maa Y-F, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: Spray-freeze-drying and stability evaluation. J Pharm Sci 2004;93(7):1912-23.
46. Zhao L, Chan K, Maa Y-F. Evaluation of alternate powder formulation processes for r-hIFN-b: Spray-freeze-drying and spray-drying. Internal report, PowderJect Vaccines, 13 October 2000.
47. Maa Y-F, Nguyen P-A, Sweeney T, Shire JS, Chung CH. Protein inhalation powders: Spray drying vs spray freeze drying. Pharm Res 1999;16(2):249-54.
48. Costantino HR, Firouzabadian L, Hogeland K, Wu C, Beganski C, Carrisquilla KG, Cardova M, Griebenow K, Zale SE, Tracy MA. Protein spray freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 2000;17:1374-81.
49. Chen D, Enders RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG. Epidermal immunization by a needle-free powder delivery technology: immunization of influenza vaccine and protection in mice. Nat Med 2000;6(10):1187-90.
50. Labrude P, Rasolomanana M, Vigneron C, Thirion C, Chaillot B. Protective effect of sucrose on spray drying of oxyhemoglobin. J Pharm Sci 1989;78:223-9.
51. Maa YF, Nguyen P, Hsu CC. Spray drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci 1998;87:152.
52. Sonner C, Maa Y-F, Lee G. Spray-freeze-drying for protein powder preparation: Particle characterization and a case study with trypsinogen stability. J Pharm Sci 2002;91:2122-39.
53. Afua Jumah N. The development of non-metallic powders for biolistic DNA delivery and the analysis of biolistic delivery by two-photon microscopy. DPhil thesis, Engineering Science, University of Oxford. 2004.
54. Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. Immune responses to hepatitis b surface antigen following epidermal powder immunization. Immun Cell Bio 2003;81:52-8.
55. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 1993;10:1-28.
56. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 1997;14(8):969-75.
57. Franks F, Hatley RHM, Mathias SF. Material science and the stable production of shelf-stable biologicals. Bio Pharm 1991;4:38-42.
58. Skrabanja AT, de Meere AL, de Ruiter RA, van den Oetelaar PJ. Lyophilization of biotechnology products. J Pharm Sci Technol 1994;48:311-7.
59. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1-60.
60. Mumenthaler M, Chung CH, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res 1994;11:12-20.
61. Pikal MJ. Freeze drying. In: Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; 2002. pp. 1299-326.
62. Pikal MJ. Heat and mass transfer in low pressure gases: Applications to freeze drying. In: Pikal MJ, editor. Freeze drying of pharmaceuticals. Lecture script, University of Connecticut, Storrs 2003.